Sanofi to focus on biopharmaceuticals and in-house drug discovery

Sanofi (Euronext: SAN) is presenting key updates to its R&D strategy and milestones for 2018 in Paris today.

Over the next few years, the company says it will shift away from small molecules to the development of biologics, with an emphasis on multi-targeting compounds.

In addition, the French drugmaker says it will increase emphasis on developing proprietary technology platforms, building on progress in multi-specific antibodies, siRNA, trigonal peptides, dual and triple agonists, and PRR-Antibody conjugates.